Skip to main content

Table 1 Baseline characteristics of the study population in Prostate Cancer data Base Sweden (PCBaSe) 3.0

From: How to model temporal changes in comorbidity for cancer patients using prospective cohort data

  Active surveillance (n = 7 544) Radical prostatectomy (n = 9 959) Curative radio therapy (n = 2 734) Total (n = 20,237)
Age, mean (sd) 65.4 (6.0) 61.7 (5.9) 64.8 (5.7) 63.5 (6.2)
Age, n (%)
 ≤55 362 (4.8) 1315 (13.2) 147 (5.4) 1824 (9.0)
 56–60 997 (13.2) 2280 (22.9) 435 (15.9) 3712 (18.3)
 61–65 2042 (27.1) 3314 (33.3) 781 (28.6) 6137 (30.3)
 66–70 2475 (32.8) 2433 (24.4) 846 (30.9) 5754 (28.4)
 70+ 1668 (22.1) 617 (6.2) 525 (19.2) 2810 (13.9)
Educational level, n (%)
 High 2116 (28.0) 3327 (33.4) 731 (26.7) 6174 (30.5)
 Low 2198 (29.1) 2485 (25.0) 841 (30.8) 5524 (27.3)
 Middle 3206 (42.5) 4109 (41.3) 1147 (42.0) 8462 (41.8)
 Missing 24 (0.3) 38 (0.4) 15 (0.5) 77 (0.4)
CCI at PCa diagnosis, n (%)
 0 6288 (83.4) 9008 (90.5) 2276 (83.2) 17,572 (86.8)
 1 734 (9.7) 596 (6.0) 295 (10.8) 1625 (8.0)
 2 371 (4.9) 268 (2.7) 108 (4.0) 747 (3.7)
 3+ 151 (2.0) 87 (0.9) 55 (2.0) 293 (1.4)
T-stage, n (%)
 T1a 513 (6.8) 106 (1.1) 17 (0.6) 636 (3.1)
 T1b 126 (1.7) 61 (0.6) 22 (0.8) 209 (1.0)
 T1c 5807 (77.0) 7152 (71.8) 1796 (65.7) 14,755 (72.9)
 T2 1078 (14.3) 2621 (26.3) 887 (32.4) 4586 (22.7)
 TX/Missing 20 (0.3) 19 (0.2) 12 (0.4) 51 (0.3)
N-stage, n (%)
 N0 443 (5.9) 980 (9.8) 146 (5.3) 1569 (7.8)
 NX 7101 (94.1) 8979 (90.2) 2588 (94.7) 18,668 (92.2)
PSA, mean (sd) 5.5 (2.0) 5.8 (1.9) 6.1 (1.9) 5.7 (2.0)
PSA, n (%)
 0–2.0 277 (3.7) 157 (1.6) 28 (1.0) 462 (2.3)
 2.1–4.0 1578 (20.9) 1874 (18.8) 368 (13.5) 3820 (18.9)
 4.1–6.0 2868 (38.0) 3910 (39.3) 991 (36.2) 7769 (38.4)
 6.1–8.0 1848 (24.5) 2568 (25.8) 838 (30.7) 5254 (26.0)
 8.1–10 973 (12.9) 1450 (14.6) 509 (18.6) 2932 (14.5)